Status
Conditions
About
The study will evaluate the long-term safety and efficacy of intravascular beta radiation therapy to treat coronary in-stent restenosis using the Beta-Cath(TM) 3.5F System; data will be collected retrospectively on patients treated with the Beta-Cath™ 3.5F System in routine clinical practice following FDA pre-market approval of the System. Outcomes will be reported up to 5 years following treatment.
Enrollment
Sex
Volunteers
Inclusion criteria
Patients who underwent on-label treatment (as defined below) with the Beta-Cath™ 3.5F System (30, 40 or 60mm) for in-stent restenosis (ISR) after coronary stenting.
Patients must have undergone brachytherapy treatment at least 6-8 months prior to enrollment in this retrospective study and the date of their treatment must be:
Exclusion criteria
200 participants in 1 patient group
Loading...
Central trial contact
Rebecca Torguson, MPH
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal